Qiuwei Pan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2386146/publications.pdf

Version: 2024-02-01

222 papers	7,974 citations	57758 44 h-index	71685 76 g-index

231 all docs	231 docs citations	231 times ranked	11609 citing authors

#	Article	IF	Citations
1	Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clinical Gastroenterology and Hepatology, 2022, 20, e573-e582.	4.4	84
2	A multiâ€regional, hierarchicalâ€tier mathematical model of the spread and control of COVIDâ€19 epidemics from epicentre to adjacent regions. Transboundary and Emerging Diseases, 2022, 69, 549-558.	3.0	9
3	Hepatitis E virus infection activates NODâ€like receptor family pyrin domainâ€containing 3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology, 2022, 75, 196-212.	7.3	19
4	Metabolic dysfunctionâ€“associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology, 2022, 75, 419-429.	7.3	64
5	Recapitulating Cholangiopathy-Associated Necroptotic Cell Death InÂVitro Using Human Cholangiocyte Organoids. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 541-564.	4.5	15
6	Highâ€dose vitamin D metabolite delivery inhibits breast cancer metastasis. Bioengineering and Translational Medicine, 2022, 7, e10263.	7.1	4
7	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. Clinical and Molecular Hepatology, 2022, 28, 183-195.	8.9	6
8	Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by metaâ€analysis: Focusing on the nonâ€overlap groups. Liver International, 2022, 42, 277-287.	3.9	60
9	Estimating the global prevalence of hepatitis E virus in swine and pork products. One Health, 2022, 14, 100362.	3.4	11
10	SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Research, 2022, 32, 322-324.	12.0	148
11	Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids. Journal of Molecular Medicine, 2022, 100, 471-484.	3.9	9
12	Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling. Antiviral Research, 2022, 197, 105228.	4.1	9
13	Recapitulating hepatitis E virusâ€“host interactions and facilitating antiviral drug discovery in human liverâ€derived organoids. Science Advances, 2022, 8, eabj5908.	10.3	28
14	Probing the direct effects of antiretroviral drugs on hepatitis EÂvirus replication in cell culture models. Liver International, 2022, 42, 716-717.	3.9	1
15	In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern. International Journal of Peptide Research and Therapeutics, 2022, 28, 28.	1.9	12
16	Optimal strategy for a dose-escalation vaccination against COVID-19 in refugee camps. AIMS Mathematics, 2022, 7, 9288-9310.	1.6	5
17	Hepatitis D. Chinese Medical Journal, 2022, Publish Ahead of Print, .	2.3	3
18	Kidney Organoids Are Capable of Forming Tumors, but Not Teratomas. Stem Cells, 2022, 40, 577-591.	3.2	3

#	Article	IF	Citations
19	Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions. Archives of Virology, 2022, 167, 1125-1130.	2.1	3
20	Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies. Hepatology, 2022, 76, 788-802.	7.3	21
21	Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations. Lancet Microbe, The, 2022, 3, e325-e326.	7.3	16
22	Mono- and combinational drug therapies for global viral pandemic preparedness. IScience, 2022, 25, 104112.	4.1	19
23	Chronic hepatitis E: Advancing research and patient care. Journal of Hepatology, 2022, 77, 1109-1123.	3.7	37
24	Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. Transplantation, 2022, 106, 2068-2075.	1.0	23
25	Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids. EBioMedicine, 2022, 81, 104132.	6.1	8
26	A proposed disease classification system for duck viral hepatitis. Poultry Science, 2022, , 102042.	3.4	0
27	Prevalence and clinical features of hepatitis E virus infection in pregnant women: A large cohort study in Inner Mongolia, China. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101536.	1.5	12
28	Systematically Mapping Clinical Features of Infections With Classical Endemic Human Coronaviruses. Clinical Infectious Diseases, 2021, 73, 554-555.	5.8	12
29	Author response to Letter to the Editor: Hepatitis E prevalence in indigenous communities from Western Brazilian Amazon. Liver International, 2021, 41, 234-234.	3.9	0
30	Cancer-Associated Fibroblasts Provide a Stromal Niche for Liver Cancer Organoids That Confers Trophic Effects and Therapy Resistance. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 407-431.	4.5	103
31	The biological process of lysineâ€tRNA charging is therapeutically targetable in liver cancer. Liver International, 2021, 41, 206-219.	3.9	9
32	Systematically comparing COVID-19 with the 2009 influenza pandemic for hospitalized patients. International Journal of Infectious Diseases, 2021, 102, 375-380.	3.3	20
33	Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review. European Journal of Clinical Investigation, 2021, 51, e13479.	3.4	16
34	TIGIT and PD1 Co-blockade Restores exÂvivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 443-464.	4.5	43
35	HEV prevalence and potential risk factors in a large multi-ethnic youth cohort in China. Virology Journal, 2021, 18, 3.	3.4	2
36	cGAS-STING effectively restricts murine norovirus infection but antagonizes the antiviral action of N-terminus of RIG-I in mouse macrophages. Gut Microbes, 2021, 13, 1959839.	9.8	16

#	Article	IF	Citations
37	The impact of COVID-19 pandemic outbreak on education and mental health of Chinese children aged 7â€“15â€‰years: an online survey. BMC Pediatrics, 2021, 21, 95.	1.7	79
38	Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. Transplantation, 2021, 105, 2362-2373.	1.0	13
39	Mathematical modelling and projecting the second wave of COVID-19 pandemic in Europe. Journal of Epidemiology and Community Health, 2021, 75, 601-603.	3.7	7
40	The dynamics of hepatitis delta virus prevalence and its potential association with hepatitis B virus vaccination. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101677.	1.5	2
41	Rotavirus-related systemic diseases: clinical manifestation, evidence and pathogenesis. Critical Reviews in Microbiology, 2021, 47, 580-595.	6.1	20
42	Lipid droplets and their interactions with other organelles in liver diseases. International Journal of Biochemistry and Cell Biology, 2021, 133, 105937.	2.8	8
43	Remodeling of the gut microbiome during Ramadan-associated intermittent fasting. American Journal of Clinical Nutrition, 2021, 113, 1332-1342.	4.7	64
44	Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. Nature Communications, 2021, 12, 2830.	12.8	35
45	Tracing genetic signatures of batâ€toâ€human coronaviruses and early transmission of North American SARSâ€CoVâ€2. Transboundary and Emerging Diseases, 2021, , .	3.0	3
46	Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin Î±1. Archives of Virology, 2021, 166, 2005-2010.	2.1	8
47	Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers, 2021, 13, 2499.	3.7	4
48	Letter to the Editor: High Mobility Group Box Protein 1 Release Is an Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia. Hepatology, 2021, 74, 2920-2921.	7.3	1
49	Effects of intermittent fasting on liver physiology and metabolism in mice. Experimental and Therapeutic Medicine, 2021, 22, 950.	1.8	12
50	A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Drugs in R and D, 2021, 21, 273-283.	2.2	20
51	The macrolide antibiotic azithromycin potently inhibits hepatitis E virus in cell culture models. International Journal of Antimicrobial Agents, 2021, 58, 106383.	2.5	6
52	Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management. Cell Death Discovery, 2021, 7, 293.	4.7	4
53	Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Virology, 2021, 564, 33-38.	2.4	34
54	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Alimentary Pharmacology and Therapeutics, 2021, 53, 432-442.	3.7	9

#	Article	IF	Citations
55	Distinct effectiveness in containing COVID-19 epidemic: Comparative analysis of two cities in China by mathematical modeling. PLOS Global Public Health, 2021, 1, e0000043.	1.6	0
56	Estimating the burden and modeling mitigation strategies of pork-related hepatitis E virus foodborne transmission in representative European countries. One Health, 2021, 13, 100350.	3.4	5
57	Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models. Scientific Reports, 2021, 11, 23465.	3.3	17
58	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Alimentary Pharmacology and Therapeutics, 2021, 53, 432-442.	3.7	23
59	Chronic hepatitis E in an immunocompetent patient. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, e66-e68.	1.5	7
60	Mitochondrial Fusion Via OPA1 and MFN1 Supports Liver Tumor Cell Metabolism and Growth. Cells, 2020, 9, 121.	4.1	60
61	Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. Journal of Infectious Diseases, 2020, 221, 1677-1687.	4.0	182
62	Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?. Trends in Immunology, 2020, 41, 851-853.	6.8	12
63	Evolutionarily missing and conserved tRNA genes in human and avian. Infection, Genetics and Evolution, 2020, 85, 104460.	2.3	1
64	2â€™-Fluoro-2â€™-deoxycytidine inhibits murine norovirus replication and synergizes MPA, ribavirin and T705. Archives of Virology, 2020, 165, 2605-2613.	2.1	0
65	Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses. Lancet Microbe, The, 2020, 1, e151.	7.3	43
66	Murine norovirus replicase augments RIG-I-like receptors-mediated antiviral interferon response. Antiviral Research, 2020, 182, 104877.	4.1	6
67	Rotavirus Infection and Cytopathogenesis in Human Biliary Organoids Potentially Recapitulate Biliary Atresia Development. MBio, 2020, 11, .	4.1	19
68	Revisiting the estimation of hepatitis D global prevalence. Journal of Hepatology, 2020, 73, 1279-1280.	3.7	13
69	Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Research, 2020, 184, 104967.	4.1	23
70	Poor Outcomes of Acute Hepatitis E in Patients With Cirrhotic Liver Diseases Regardless of Etiology. Open Forum Infectious Diseases, 2020, 7, ofaa107.	0.9	6
71	Drug screening identifies gemcitabine inhibiting rotavirus through alteration of pyrimidine nucleotide synthesis pathway. Antiviral Research, 2020, 180, 104823.	4.1	20
72	Lipopolysaccharide restricts murine norovirus infection in macrophages mainly through NF-kB and JAK-STAT signaling pathway. Virology, 2020, 546, 109-121.	2.4	11

#	Article	IF	Citations
73	Estimating Global Epidemiology of Low-Pathogenic Human Coronaviruses in Relation to the COVID-19 Context. Journal of Infectious Diseases, 2020, 222, 695-696.	4.0	16
74	Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses. Trends in Pharmacological Sciences, 2020, 41, 501-503.	8.7	7
75	A simplified qPCR method revealing tRNAome remodeling upon infection by genotype 3 hepatitis E virus. FEBS Letters, 2020, 594, 2005-2015.	2.8	5
76	Unique challenges to control the spread of COVID-19 in the Middle East. Journal of Infection and Public Health, 2020, 13, 1247-1250.	4.1	20
77	Potential association between COVID-19 mortality and health-care resource availability. The Lancet Global Health, 2020, 8, e480.	6.3	593
78	MDA5 against enteric viruses through induction of interferon-like response partially via the JAK-STAT cascade. Antiviral Research, 2020, 176, 104743.	4.1	16
79	Guanylate-binding protein 2 orchestrates innate immune responses against murine norovirus and is antagonized by the viral protein NS7. Journal of Biological Chemistry, 2020, 295, 8036-8047.	3.4	23
80	The global epidemiology of hepatitis E virus infection: A systematic review and metaâ€analysis. Liver International, 2020, 40, 1516-1528.	3.9	115
81	LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nature Communications, 2020, 11, 1961.	12.8	49
82	Hepatitis E virus seroprevalence in pets in the Netherlands and the permissiveness of canine liver cells to the infection. Irish Veterinary Journal, 2020, 73, 6.	2.1	11
83	Mathematical analysis of a human papillomavirus transmission model with vaccination and screening. Mathematical Biosciences and Engineering, 2020, 17, 5449-5476.	1.9	9
84	Sensitivity analysis and optimal treatment control for a mathematical model of Human Papillomavirus infection. AIMS Mathematics, 2020, 5, 2646-2670.	1.6	4
85	Mitochondrial electron transport chain complex III sustains hepatitis E virus replication and represents an antiviral target. FASEB Journal, 2019, 33, 1008-1019.	0.5	22
86	Quality of Symptom-Based Diagnosis of Rotavirus Infection Based on Mathematical Modeling. Advances in Intelligent Systems and Computing, 2019, , 555-566.	0.6	0
87	Incidence, predictors and prognosis of genotype 4 hepatitis E related liver failure: A tertiary nested caseâ€control study. Liver International, 2019, 39, 2291-2300.	3.9	15
88	FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-ÎºB-RIPK1-caspase axis. Antiviral Research, 2019, 170, 104588.	4.1	17
89	A functional variant in the miRâ€142 promoter modulating its expression and conferring risk of Alzheimer disease. Human Mutation, 2019, 40, 2131-2145.	2.5	23
90	Mitochondria in the biology, pathogenesis, and treatment of hepatitis virus infections. Reviews in Medical Virology, 2019, 29, e2075.	8.3	16

#	Article	IF	Citations
91	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Scientific Reports, 2019, 9, 10677.	3.3	37
92	GITR ligation enhances functionality of tumorâ€infiltrating T cells in hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 1111-1124.	5.1	42
93	The Interplay between Host Innate Immunity and Hepatitis E Virus. Viruses, 2019, 11, 541.	3.3	19
94	Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. Journal of Infection, 2019, 79, 262-276.	3.3	8
95	Phylogenetic and immunoinformatic analysis of VP4, VP7, and NSP4 genes of rotavirus strains circulating in children with acute gastroenteritis in Indonesia. Journal of Medical Virology, 2019, 91, 1776-1787.	5.0	3
96	Co-occurrence of heterozygous mutations in COL1A1 and SERPINF1 in a high-risk pregnancy complicated by osteogenesis imperfecta. Journal of Genetics, 2019, 98, 1.	0.7	0
97	Norovirus and rotavirus infections in children less than five years of age hospitalized with acute gastroenteritis in Indonesia. Archives of Virology, 2019, 164, 1515-1525.	2.1	14
98	Errors in translational decoding: tRNA wobbling or misincorporation?. PLoS Genetics, 2019, 15, e1008017.	3.5	27
99	Suppression of pyrimidine biosynthesis by targeting DHODH enzyme robustly inhibits rotavirus replication. Antiviral Research, 2019, 167, 35-44.	4.1	35
100	The Eukaryotic Translation Initiation Factor 4F Complex Restricts Rotavirus Infection via Regulating the Expression of IRF1 and IRF7. International Journal of Molecular Sciences, 2019, 20, 1580.	4.1	11
101	No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients. Hepatology, 2019, 69, 1846-1847.	7.3	14
102	Efficacy of Different Endoscopic Stents in the Management of Postoperative Biliary Strictures. Journal of Clinical Gastroenterology, 2019, 53, 418-426.	2.2	11
103	Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients. Transplantation, 2019, 103, 929-937.	1.0	16
104	The Burden of Human Papillomavirus andChlamydia trachomatisCoinfection in Women: A Large Cohort Study in Inner Mongolia, China. Journal of Infectious Diseases, 2019, 219, 206-214.	4.0	21
105	Sofosbuvir directly promotes the clonogenic capability of human hepatocellular carcinoma cells. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e79-e81.	1.5	1
106	Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. Journal of Molecular Medicine, 2019, 97, 77-88.	3.9	14
107	Directâ€acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and metaâ€analysis. Transplant Infectious Disease, 2019, 21, e13047.	1.7	15
108	Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis, 2019, 40, 155-163.	2.8	9

#	Article	IF	Citations
109	RDW, NLR and RLR in predicting liver failure and prognosis in patients with hepatitis E virus infection. Clinical Biochemistry, 2019, 63, 24-31.	1.9	29
110	Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 117-125.	7.4	50
111	The genetic divergences of codon usage shed new lights on transmission of hepatitis E virus from swine to human. Infection, Genetics and Evolution, 2019, 68, 23-29.	2.3	34
112	Recombinant identification, molecular classification and proposed reference genomes for hepatitis delta virus. Journal of Viral Hepatitis, 2019, 26, 183-190.	2.0	13
113	Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/Î²-Catenin Signaling. Molecular Cancer Research, 2019, 17, 521-531.	3.4	8
114	Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis, 2019, 40, 145-154.	2.8	30
115	Outcome of a screening program for the prevention of neonatal early-onset group B Streptococcus infection: a population-based cohort study in Inner Mongolia, China. Journal of Medical Microbiology, 2019, 68, 803-811.	1.8	13
116	Significance of continuous rotavirus and norovirus surveillance in Indonesia. World Journal of Pediatrics, 2018, 14, 4-12.	1.8	12
117	Hepatitis E virus infection in HIVâ€infected patients: A large cohort study in Yunnan province, China. Journal of Medical Virology, 2018, 90, 1121-1127.	5.0	12
118	Chronic Hepatitis E in a Renal Transplant Recipient: The First Report of Genotype 4 Hepatitis E Virus Caused Chronic InfectionÂin Organ Recipient. Gastroenterology, 2018, 154, 1199-1201.	1.3	38
119	Immunity against hepatitis E virus infection: Implications for therapy and vaccine development. Reviews in Medical Virology, 2018, 28, e1964.	8.3	11
120	PI3K-Akt-mTOR axis sustains rotavirus infection via the 4E-BP1 mediated autophagy pathway and represents an antiviral target. Virulence, 2018, 9, 83-98.	4.4	51
121	Genotype-specific acquisition, evolution and adaptation of characteristic mutations in hepatitis E virus. Virulence, 2018, 9, 121-132.	4.4	18
122	The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response. Hepatology, 2018, 67, 2096-2112.	7.3	37
123	Prevalence of human papillomavirus infection in women in the Autonomous Region of Inner Mongolia: A populationâ€based study of a Chinese ethnic minority. Journal of Medical Virology, 2018, 90, 148-156.	5.0	16
124	Hepatitis E virus infection in acute non-traumatic neuropathy: A large prospective case-control study in China. EBioMedicine, 2018, 36, 122-130.	6.1	30
125	Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. Scientific Reports, 2018, 8, 12471.	3.3	22
126	A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation. Digestive Diseases and Sciences, 2018, 63, 2653-2661.	2.3	7

#	Article	IF	Citations
127	Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids. Scientific Reports, 2018, 8, 8341.	3.3	28
128	Conservation and variation of the hepatitis E virus ORF2 capsid protein. Gene, 2018, 675, 157-164.	2.2	8
129	The Challenges of Long-Term Transcriptional Gene Silencing by RNA Viruses. Trends in Biochemical Sciences, 2018, 43, 649-650.	7.5	5
130	IRF-1, RIG-I and MDA5 display potent antiviral activities against norovirus coordinately induced by different types of interferons. Antiviral Research, 2018, 155, 48-59.	4.1	40
131	Incompatible Translation Drives a Convergent Evolution and Viral Attenuation During the Development of Live Attenuated Vaccine. Frontiers in Cellular and Infection Microbiology, 2018, 8, 249.	3.9	13
132	Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
133	Effective Treatment of Chronic Proliferative Cholangitis by Local Gentamicin Infusion in Rabbits. BioMed Research International, 2018, 2018, 1-6.	1.9	1
134	The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection. Veterinary Research Communications, 2018, 42, 309-313.	1.6	8
135	TNF-Î± exerts potent anti-rotavirus effects via the activation of classical NF-ÎºB pathway. Virus Research, 2018, 253, 28-37.	2.2	36
136	6-Thioguanine inhibits rotavirus replication through suppression of Rac1 GDP/GTP cycling. Antiviral Research, 2018, 156, 92-101.	4.1	36
137	PD-L1, Galectin-9 and CD8⁺ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. OncoImmunology, 2017, 6, e1273309.	4.6	117
138	Transcriptional Regulation of Antiviral Interferon-Stimulated Genes. Trends in Microbiology, 2017, 25, 573-584.	7.7	151
139	Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. Antiviral Research, 2017, 140, 1-12.	4.1	13
140	Direct-acting antiviral therapy for hepatitis E virus?. The Lancet Gastroenterology and Hepatology, 2017, 2, 154-155.	8.1	11
141	RIGâ€I is a key antiviral interferonâ€stimulated gene against hepatitis E virus regardless of interferon production. Hepatology, 2017, 65, 1823-1839.	7.3	63
142	Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Science Signaling, 2017, 10, .	3.6	64
143	Noncanonical Antiviral Mechanisms of ISGs: Dispensability of Inducible Interferons. Trends in Immunology, 2017, 38, 1-2.	6.8	21
144	Epigenome-Wide Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic Steatosis. Gastroenterology, 2017, 153, 1096-1106.e2.	1.3	52

#	Article	IF	Citations
145	Nucleoside analogue 2â€™-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin. Archives of Virology, 2017, 162, 2989-2996.	2.1	24
146	Antibodies Against Immune Checkpoint Molecules RestoreÂFunctions of Tumor-Infiltrating T Cells in HepatocellularÂCarcinomas. Gastroenterology, 2017, 153, 1107-1119.e10.	1.3	309
147	Should Nivolumab-Induced Colitis Be Treated by Infliximab?. Clinical Gastroenterology and Hepatology, 2017, 15, 1637.	4.4	3
148	Hepatitis E Virus Infects Neurons and Brains. Journal of Infectious Diseases, 2017, 215, 1197-1206.	4.0	94
149	Action and function of Wnt/Î²-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma. Journal of Gastroenterology, 2017, 52, 419-431.	5.1	66
150	Mushroom poisoning: an overlooked cause of acute liver injury in China. Liver International, 2017, 37, 468-469.	3.9	3
151	Matrix Metalloproteinases (MMPs) in Liver Diseases. Journal of Clinical and Experimental Hepatology, 2017, 7, 367-372.	0.9	83
152	Reply to Sayed and Meuleman. Journal of Infectious Diseases, 2017, 216, 920-921.	4.0	0
153	Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Long-term Follow-up study in Yunnan, China. Scientific Reports, 2017, 7, 9595.	3.3	16
154	Dynamics of Proliferative and Quiescent Stem Cells in Liver Homeostasis and Injury. Gastroenterology, 2017, 153, 1133-1147.	1.3	39
155	Cytoplasmic rods and rings in mycophenolic acid treatment. Liver International, 2017, 37, 1742-1743.	3.9	1
156	Genetically Engineered Bacteria for Treating Human Disease. Trends in Pharmacological Sciences, 2017, 38, 763-764.	8.7	8
157	Opposing Effects of Nitazoxanide on Murine and Human Norovirus. Journal of Infectious Diseases, 2017, 216, 780-782.	4.0	16
158	Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	21
159	Reply to Wang et al. Journal of Infectious Diseases, 2017, 215, 1341-1342.	4.0	0
160	The global burden of hepatitis E outbreaks: a systematic review. Liver International, 2017, 37, 19-31.	3.9	80
161	Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. Clinical and Experimental Gastroenterology, 2017, Volume 10, 203-209.	2.3	9
162	Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 15193-15204.	1.8	25

#	Article	IF	Citations
163	Identification of Rotavirus Strains Causing Diarrhoea in Children under Five Years of Age in Yogyakarta, Indonesian. The Malaysian Journal of Medical Sciences, 2017, 24, 68-77.	0.5	7
164	Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis. Hepatology, 2016, 64, 350-359.	7.3	166
165	Convergent Transcription of Interferon-stimulated Genes by TNF-Î± and IFN-Î± Augments Antiviral Activity against HCV and HEV. Scientific Reports, 2016, 6, 25482.	3.3	56
166	Targeting Viral Polymerase for Treating Hepatitis E Infection: How Far Are We?. Gastroenterology, 2016, 150, 1690.	1.3	6
167	Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development. Antiviral Research, 2016, 133, 41-49.	4.1	50
168	Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of Î²-Catenin Signaling. Neoplasia, 2016, 18, 711-723.	5.3	37
169	Distinct Antiviral Potency of Sofosbuvir Against Hepatitis CÂand E Viruses. Gastroenterology, 2016, 151, 1251-1253.	1.3	26
170	IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFNâ€stimulated genes. FASEB Journal, 2016, 30, 3352-3367.	0.5	54
171	Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. Journal of Viral Hepatitis, 2016, 23, 294-304.	2.0	27
172	Rhesus macaques persistently infected with hepatitis E shed virus into urine. Journal of Hepatology, 2016, 64, 1446-1447.	3.7	30
173	Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2834-2848.	3.2	64
174	Anti-Tumor Effects of Metformin in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0127967.	2.5	32
175	Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. Molecular Medicine, 2015, 21, 792-802.	4.4	14
176	Virusâ€“host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. Gut, 2015, 64, 852-853.	12.1	1
177	Gene Therapies for Hepatitis C Virus. Advances in Experimental Medicine and Biology, 2015, 848, 1-29.	1.6	8
178	Rotavirus in Organ Transplantation: Drug-Virus-Host Interactions. American Journal of Transplantation, 2015, 15, 585-593.	4.7	31
179	Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. OncoImmunology, 2015, 4, e1008355.	4.6	78
180	Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. Antiviral Research, 2015, 123, 120-131.	4.1	156

#	Article	IF	Citations
181	Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication. Antiviral Research, 2015, 124, 11-19.	4.1	22
182	Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. British Journal of Cancer, 2015, 112, 1911-1920.	6.4	36
183	GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cellsex vivo. OncoImmunology, 2015, 4, e1051297.	4.6	45
184	SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene, 2015, 34, 5055-5068.	5.9	57
185	Inhibition of hepatitis E virus replication by proteasome inhibitor is nonspecific. Archives of Virology, 2015, 160, 435-439.	2.1	10
186	Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transplantation, 2014, 20, 261-269.	2.4	24
187	Chronic hepatitis E in solid-organ transplantation. Current Opinion in Infectious Diseases, 2014, 27, 303-308.	3.1	19
188	Ribavirin Inhibits In Vitro Hepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon. Antimicrobial Agents and Chemotherapy, 2014, 58, 267-273.	3.2	126
189	Detection of spontaneous tumorigenic transformation during culture expansion of human mesenchymal stromal cells. Experimental Biology and Medicine, 2014, 239, 105-115.	2.4	110
190	Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation. Stem Cell Reports, 2014, 3, 606-619.	4.8	33
191	Multipotent mesenchymal stromal cells in liver cancer: Implications for tumor biology and therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 439-445.	7.4	10
192	Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus. Gastroenterology, 2014, 146, 1775-1783.	1.3	158
193	Rapamycin and everolimus facilitate hepatitis E virus replication: Revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Journal of Hepatology, 2014, 61, 746-754.	3.7	97
194	DMS triggers apoptosis associated with the inhibition of SPHK1/NF-Îº B activation and increase in intracellular Ca2+ concentration in human cancer cells. International Journal of Molecular Medicine, 2014, 33, 17-24.	4.0	24
195	Anti-diabetic drugs, insulin and metformin, have no direct interaction with hepatitis C virus infection or anti-viral interferon response. AIMS Molecular Science, 2014, 1, 49-58.	0.5	0
196	Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. Reviews in Medical Virology, 2013, 23, 295-304.	8.3	61
197	Overestimation of hematopoietic stem cell frequencies in human liver grafts. Hepatology, 2013, 57, 2547-2549.	7.3	3
198	Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13109-13113.	7.1	422

#	Article	IF	Citations
199	Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus. Gastroenterology, 2013, 144, 761-770.	1.3	63
200	Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells. Cytotherapy, 2013, 15, 1352-1361.	0.7	40
201	Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Carcinogenesis, 2013, 34, 2330-2340.	2.8	50
202	Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut, 2012, 61, 1330-1339.	12.1	150
203	Antiviral or proviral action of mycophenolic acid in hepatitis B infection?. Hepatology, 2012, 56, 1586-1587.	7.3	8
204	New targets for treatment against HCV infection. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 505-515.	2.4	1
205	Secreted Factors of Human Liver-Derived Mesenchymal Stem Cells Promote Liver Regeneration Early After Partial Hepatectomy. Stem Cells and Development, 2012, 21, 2410-2419.	2.1	90
206	Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology, 2012, 55, 1673-1683.	7.3	91
207	Virusâ€“drug interactionsâ€”molecular insight into immunosuppression and HCV. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 355-362.	17.8	19
208	A dynamic perspective of RNAi library development. Trends in Biotechnology, 2012, 30, 206-215.	9.3	27
209	Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transplantation, 2012, 18, 290-297.	2.4	177
210	Telaprevir/boceprevir era: From bench to bed and back. World Journal of Gastroenterology, 2012, 18, 6183.	3.3	22
211	AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?. Expert Opinion on Biological Therapy, 2011, 11, 315-327.	3.1	28
212	Disturbance of the microRNA pathway by commonly used lentiviral shRNA libraries limits the application for screening host factors involved in hepatitis C virus infection. FEBS Letters, 2011, 585, 1025-1030.	2.8	25
213	Mobilization of hepatic mesenchymal stem cells from human liver grafts. Liver Transplantation, 2011, 17, 596-609.	2.4	44
214	Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. Hepatology, 2011, 53, 1400-1401.	7.3	10
215	Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-Î±. Liver Transplantation, 2010, 16, 520-526.	2.4	21
216	Combined antiviral activity of interferon-Î± and RNA interference directed against hepatitis C without affecting vector delivery and gene silencing. Journal of Molecular Medicine, 2009, 87, 713-722.	3.9	46

#	Article	IF	Citations
217	Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert Opinion on Biological Therapy, 2009, 9, 713-724.	3.1	20
218	Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta OncolÃ³gica, 2008, 47, 135-144.	1.8	33
219	Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacologica Sinica, 2007, 28, 1996-2004.	6.1	25
220	Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Molecular and Cellular Biochemistry, 2007, 304, 315-323.	3.1	37
221	A novel strategy for cancer gene therapy: RNAi. Science Bulletin, 2006, 51, 1145-1151.	1.7	12
222	The Global Burden of Hepatitis E Virus Infection: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0